Patents by Inventor Andrew J. Malcolm
Andrew J. Malcolm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20040198953Abstract: This invention relates to the production of polyclonal and monoclonal antibodies to specific sites of rapamycin (Sirolimus). The reactivity of these poly and monoclonal antibodies make them particularly useful for immunoassays for therapeutic drug monitoring (TDM). These immunoassays or TDM kits may include polyclonal or monoclonal antibodies to specific sites of rapamycin. These kits may also include various combinations of polyclonal antibodies, polyclonal and monoclonal antibodies or a panel of monoclonal antibodies. Rapamycin conjugate immunogens are prepared for the immunization of a host animal to produce antibodies directed against specific regions of the rapamycin molecule. By determining the specific binding region of particular antibody, immunoassays which are capable of distinguishing between the parent molecule, active metabolites, inactive metabolites and other structurally similar immunosuppressant compounds are developed.Type: ApplicationFiled: January 13, 2004Publication date: October 7, 2004Inventors: Randall W. Yatscoff, Andrew J. Malcolm, Selvaraj Naicker
-
Publication number: 20040198952Abstract: This invention relates to the production of polyclonal and monoclonal antibodies to specific regions of cyclosporine (CSA) and/or CSA metabolites/derivatives. The reactivity of these polyclonal and monoclonal antibodies make them particularly useful for immunoassays for therapeutic drug monitoring (TDM). These immunoassays or TDM kits may include polyclonal or monoclonal antibodies to specific sites of CSA and/or CSA metabolites. These kits may also include various combinations of polyclonal antibodies, polyclonal and monoclonal antibodies or a panel of monoclonal antibodies. Cyclosporine or CSA metabolite conjugate immunogens are prepared for the immunization of a host animal to produce antibodies directed against specific regions of the CSA or CSA metabolite molecule.Type: ApplicationFiled: January 13, 2004Publication date: October 7, 2004Inventors: Randall W. Yatscoff, Andrew J. Malcolm, S. Selvaraj Naicker
-
Patent number: 6713266Abstract: This invention relates to the production of polyclonal and monoclonal antibodies to specific regions of cyclosporine (CSA) and/or CSA metabolites/derivatives. The reactivity of these polyclonal and monoclonal antibodies make them particularly useful for immunoassays for therapeutic drug monitoring (TDM). These immunoassays or TDM kits may include polyclonal or monoclonal antibodies to specific sites of CSA and/or CSA metabolites. These kits may also include various combinations of polyclonal antibodies, polyclonal and monoclonal antibodies or a panel of monoclonal antibodies. Cyclosporine or CSA metabolite conjugate immunogens are prepared for the immunization of a host animal to produce antibodies directed against specific regions of the CSA or CSA metabolite molecule.Type: GrantFiled: August 30, 2000Date of Patent: March 30, 2004Assignee: Isodiagnostika Inc.Inventors: Randall W. Yatscoff, Andrew J. Malcolm, S. Selvaraj Naicker
-
Patent number: 6709873Abstract: This invention relates to the production of polyclonal and monoclonal antibodies to specific sites of rapamycin (Sirolimus). The reactivity of these poly and monoclonal antibodies make them particularly useful for immunoassays for therapeutic drug monitoring (TDM). These immunoassays or TDM kits may include polyclonal or monoclonal antibodies to specific sites of rapamycin. These kits may also include various combinations of polyclonal antibodies, polyclonal and monoclonal antibodies or a panel of monoclonal antibodies. Rapamycin conjugate immunogens are prepared for the immunization of a host animal to produce antibodies directed against specific regions of the rapamycin molecule. By determining the specific binding region of particular antibody, immunoassays which are capable of distinguishing between the parent molecule, active metabolites, inactive metabolites and other structurally similar immunosuppressant compounds are developed.Type: GrantFiled: August 15, 2000Date of Patent: March 23, 2004Assignee: Isodiagnostika Inc.Inventors: Randall W. Yatscoff, Andrew J. Malcolm, Selvaraj Naicker
-
Patent number: 6686454Abstract: This invention relates to the production of polyclonal and monoclonal antibodies to specific regions of cyclosporine (CSA) and/or CSA metabolites/derivatives. The reactivity of these polyclonal and monoclonal antibodies make them particularly useful for immunoassays for therapeutic drug monitoring (TDM). These immunoassays or TDM kits may include polyclonal or monoclonal antibodies to specific sites of CSA and/or CSA metabolites. These kits may also include various combinations of polyclonal antibodies, polyclonal and monoclonal antibodies or a panel of monoclonal antibodies. Cyclosporine or CSA metabolite conjugate immunogens are prepared for the immunization of a host animal to produce antibodies directed against specific regions of the CSA or CSA metabolite molecule.Type: GrantFiled: September 3, 1999Date of Patent: February 3, 2004Assignee: Isotechnika, Inc.Inventors: Randall W. Yatscoff, Andrew J. Malcolm, S. Selvaraj Naicker
-
Publication number: 20030228324Abstract: Peptide compositions and methods of producing and using same are provided. The peptide compositions are based on pilin peptides derived from Pseudomonas aeruginosa. The compositions include antigens and antibodies immunoreactive against the antigens. The compositions can be utilized in vaccines for treatment purposes, such as to treat or prevent infection associated with Pseudomonas aeruginosa and/or other infectious agents. Further, the compositions can be utilized to produce antibody or monoclonal antibody therapeutic to treat or prevent infection associated with Pseudomonas aeruginosa and/or other infectious agents.Type: ApplicationFiled: May 9, 2003Publication date: December 11, 2003Inventors: Andrew J. Malcolm, Rita L. Marcotte, Garry Lund, Robert Hodges
-
Patent number: 6607723Abstract: Antibody-mediated xenograft rejection is attenuated by (1) removing preformed antibodies to various identified carbohydrate xenoantigens from the recipient's circulation prior to transplantation by extracorporeal perfusion of the recipient's blood over a biocompatible solid support to which the xenoantigens are bound and/or (2) parenterally administering a xenoantibody-inhibiting amount of an identified xenoantigen to the recipient shortly before graft revascularization and thereafter.Type: GrantFiled: June 2, 1995Date of Patent: August 19, 2003Assignees: Alberta Research Council, Integris Baptist Medical Center, Inc.Inventors: A. Heather Good, David K.C. Cooper, Andrew J. Malcolm
-
Patent number: 6168796Abstract: This invention provides compositions comprising an oligosaccharide of S. pneumoniae serotype 8 useful for stimulating an immune response to an antigen, methods of providing protective immunization against a bacterial pathogen using these compositions, methods of augmenting an immunogenic response to an antigen by administering these S. pneumoniae serotype 8 oligosaccharide compositions along with the antigen, and methods of making the immunostimulatory compositions described above.Type: GrantFiled: January 6, 1999Date of Patent: January 2, 2001Assignee: Alberta Research CouncilInventor: Andrew J. Malcolm
-
Patent number: 6132723Abstract: The invention provides immunogenic oligosaccharide compositions and methods of making and using them. In particular, the compositions comprise oligosaccharides covalently coupled to carrier protein, wherein the resultant conjugate has been shown to contain specific immunogenic epitopes and elicits a protectively immunogenic response.Type: GrantFiled: July 14, 1998Date of Patent: October 17, 2000Assignee: Alberta Research CouncilInventor: Andrew J. Malcolm
-
Patent number: 5977079Abstract: Antibody-mediated xenograft rejection is attenuated by (1) removing preformed antibodies to various identified carbohydrate xenoantigens from the recipient's circulation prior to transplantation by extracorporeal perfusion of the recipient's blood over a biocompatible solid support to which the xenoantigens are bound and/or (2) parenterally administering a xenoantibody-inhibiting amount of an identified xenoantigen to the recipient shortly before graft revascularization and thereafter.Type: GrantFiled: September 23, 1997Date of Patent: November 2, 1999Assignees: Alberta Research Council Edmonton, Integris Baptist Medical Center, Inc.Inventors: A. Heather Good, David K.C. Cooper, Andrew J. Malcolm
-
Patent number: 5916571Abstract: The invention provides compositions comprising an oligosaccharide of S. pneumoniae serotype 8 useful for stimulating an immune response to an antigen, methods of providing protective immunization against a bacterial pathogen using these compositions, methods of augmenting an immunogenic response to an antigen by administering these S. pneumoniae serotype 8 oligosaccharide compositions along with the antigen, and methods of making the immunostimulatory compositions described above.Type: GrantFiled: January 22, 1997Date of Patent: June 29, 1999Assignee: Alberta Research CouncilInventor: Andrew J. Malcolm
-
Patent number: 5866132Abstract: The invention provides immunogenic oligosaccharide compositions and methods of making and using them. In particular, the compositions comprise oligosaccharides covalently coupled to carrier protein, wherein the resultant conjugate has been shown to contain specific immunogenic epitopes and elicits a protectively immunogenic response.Type: GrantFiled: June 7, 1995Date of Patent: February 2, 1999Assignee: Alberta Research CouncilInventor: Andrew J. Malcolm
-
Patent number: 5855901Abstract: The invention provides compositions comprising an oligosaccharide of S. pneumoniae serotype 8 useful for stimulating an immune response to an antigen, methods of providing protective immunization against a bacterial pathogen using these compositions, methods of augmenting an immunogenic response to an antigen by administering these S. pneumoniae serotype 8 oligosaccharide compositions along with the antigen, and methods of making the immunostimulatory compositions described above.Type: GrantFiled: January 22, 1997Date of Patent: January 5, 1999Assignee: Alberta Research CouncilInventor: Andrew J. Malcolm
-
Patent number: 5807553Abstract: The invention provides immunogenic oligosaccharide compositions and methods of making and using them. In particular, the compositions comprise oligosaccharides covalently coupled to carrier protein, wherein the resultant conjugate has been shown to contain specific immunogenic epitopes and elicits a protectively immunogenic response.Type: GrantFiled: May 13, 1996Date of Patent: September 15, 1998Assignee: Alberta Research CouncilInventor: Andrew J. Malcolm
-
Patent number: 5767093Abstract: Antibody-mediated xenograft rejection is attenuated by parenterally administering a xenoantibody-inhibiting amount of an identified carbohydrate xenoantigen to the recipient shortly before graft revascularization and thereafter.Type: GrantFiled: June 2, 1995Date of Patent: June 16, 1998Assignees: Alberta Research Council, INTEGRIS Baptist Medical Center, Inc.Inventors: A. Heather Good, David K. C. Cooper, Andrew J. Malcolm
-
Patent number: 5695759Abstract: Antibody-mediated xenograft rejection is attenuated by (1) removing preformed antibodies to various identified carbohydrate xenoantigens from the recipient's circulation prior to transplantation by extracorporeal perfusion of the recipient's blood over a biocompatible solid support to which the xenoantigens are bound and/or (2) parenterally administering a xenoantibody-inhibiting amount of an identified xenoantigen to the recipient shortly before graft revascularization and thereafter.Type: GrantFiled: June 2, 1995Date of Patent: December 9, 1997Assignees: Alberta Research Council, Integris Baptist Medical Ctr.Inventors: A. Heather Good, David K. C. Cooper, Andrew J. Malcolm
-
Patent number: 5695768Abstract: The invention provides compositions comprising an oligosaccharide of S. pneumoniae serotype 8 useful for stimulating an immune response to an antigen, methods of providing protective immunization against a bacterial pathogen using these compositions, methods of augmenting an immunogenic response to an antigen by administering these S. pneumoniae serotype 8 oligosaccharide compositions along with the antigen, and methods of making the immunostimulatory compositions described above.Type: GrantFiled: June 7, 1995Date of Patent: December 9, 1997Assignee: Alberta Research CouncilInventor: Andrew J. Malcolm
-
Patent number: 5651968Abstract: Antibody-mediated xenograft rejection is attenuated by (1) removing preformed antibodies to various identified carbohydrate xenoantigens from the recipient's circulation prior to transplantation by extracorporeal perfusion of the recipient's blood over a biocompatible solid support to which the xenoantigens are bound and/or (2) parenterally administering a xenoantibody-inhibiting amount of an identified xenoantigen to the recipient shortly before graft revascularization and thereafter.Type: GrantFiled: August 21, 1992Date of Patent: July 29, 1997Assignee: Alberta Research CouncilInventors: A. Heather Good, David K. C. Cooper, Andrew J. Malcolm